Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2208041rdf:typepubmed:Citationlld:pubmed
pubmed-article:2208041lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2208041lifeskim:mentionsumls-concept:C0152035lld:lifeskim
pubmed-article:2208041lifeskim:mentionsumls-concept:C0024305lld:lifeskim
pubmed-article:2208041lifeskim:mentionsumls-concept:C0205462lld:lifeskim
pubmed-article:2208041lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:2208041lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:2208041pubmed:issue8lld:pubmed
pubmed-article:2208041pubmed:dateCreated1990-11-16lld:pubmed
pubmed-article:2208041pubmed:abstractTextThe histologic subtypes and survival of 840 Chinese patients with non-Hodgkin's lymphoma (NHL) were reviewed. All cases were classified according to the Rappaport and Kiel systems and the Working Formulation (WF). A low incidence of nodular/follicular lymphomas (12%) was observed. The most common histologic subtypes were diffuse histiocytic, diffuse centroblastic, and diffuse large cell lymphomas, according to Rappaport, Kiel, and the WF, respectively. A high proportion (24%) of the cases were unclassifiable, according to Kiel, because of the precise terms of the classification. The "favorable"-prognosis NHL, according to Rappaport, or the low-grade NHL, according to Kiel and the WF, had a more indolent clinical course. However, except for the nodular mixed (Rappaport) or follicular mixed (WF) lymphomas which appeared to behave like the more aggressive NHL, a plateau was not seen in the survival curves of our patients with other kinds of favorable-prognosis or low-grade NHL, indicating the lack of curative potential of these tumors. The lymphoplasmacytoid lymphoma, according to Kiel, also appeared to have a more aggressive clinical course. A plateau was seen in most of the other survival curves of patients with the more aggressive tumors, indicating the prospect of cure. However, the prognosis of the very aggressive tumors such as the diffuse lymphoblastic and diffuse small noncleaved cell lymphomas, according to the WF, remains very poor with a median survival of less than 10 months.lld:pubmed
pubmed-article:2208041pubmed:languageenglld:pubmed
pubmed-article:2208041pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2208041pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2208041pubmed:statusMEDLINElld:pubmed
pubmed-article:2208041pubmed:monthOctlld:pubmed
pubmed-article:2208041pubmed:issn0008-543Xlld:pubmed
pubmed-article:2208041pubmed:authorpubmed-author:ToddDDlld:pubmed
pubmed-article:2208041pubmed:authorpubmed-author:ChiuEElld:pubmed
pubmed-article:2208041pubmed:authorpubmed-author:HoF CFClld:pubmed
pubmed-article:2208041pubmed:authorpubmed-author:ChanT KTKlld:pubmed
pubmed-article:2208041pubmed:authorpubmed-author:LokeS LSLlld:pubmed
pubmed-article:2208041pubmed:authorpubmed-author:LiangRRlld:pubmed
pubmed-article:2208041pubmed:issnTypePrintlld:pubmed
pubmed-article:2208041pubmed:day15lld:pubmed
pubmed-article:2208041pubmed:volume66lld:pubmed
pubmed-article:2208041pubmed:ownerNLMlld:pubmed
pubmed-article:2208041pubmed:authorsCompleteYlld:pubmed
pubmed-article:2208041pubmed:pagination1850-5lld:pubmed
pubmed-article:2208041pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:meshHeadingpubmed-meshheading:2208041-...lld:pubmed
pubmed-article:2208041pubmed:year1990lld:pubmed
pubmed-article:2208041pubmed:articleTitleHistologic subtypes and survival of Chinese patients with non-Hodgkin's lymphomas.lld:pubmed
pubmed-article:2208041pubmed:affiliationDepartment of Medicine, University of Hong Kong, Queen Mary Hospital.lld:pubmed
pubmed-article:2208041pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2208041pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed